Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a strong rebound, driven by a new policy aimed at promoting the retail drug industry and enhancing the accessibility of innovative drugs [3][9]. Group 1: Market Performance - On January 23, the Hong Kong Stock Connect innovative drug ETF (520880) surged by 2%, with leading stocks such as Cloudtop and InnoCare Biologics showing significant gains [1][8]. - The ETF has seen over 230 million yuan in net subscriptions this week, bringing its total shares to 4.538 billion, a new historical high [3][9]. Group 2: Policy Impact - A new policy issued by the Ministry of Commerce and other departments encourages the sale of innovative drugs and reference preparations in retail pharmacies, aiming to improve the purchasing experience [3][9]. - The policy is designed to enhance the professional service capabilities of the retail drug sector and provide pathways for high-value innovative drugs, such as CAR-T, to fill insurance coverage gaps [3][9]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) tracks an index that has three unique advantages: it exclusively covers innovative drug companies, has a high concentration of leading firms, and manages risks associated with less liquid stocks [5][11]. - The top ten stocks in the ETF account for over 73% of its weight, indicating a strong representation of leading innovative drug companies [6][13].

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak price of 2.88% and currently up by 2.52% [1] - Key performing stocks within the ETF include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1] - The market anticipates more international collaboration opportunities for Chinese innovative drug companies following the JPM Healthcare Conference held from January 12 to 15, 2026 [2][3] Group 2 - West Securities predicts that the Hong Kong innovative drug sector will continue to show structural trends in 2026, with accelerated BD (business development) overseas driving the convergence of drug price differences between China and the U.S. [3] - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [3] - The top ten weighted stocks in the Hang Seng Stock Connect Innovative Drug Select Index include Kangfang Biologics, CSPC Pharmaceutical Group, BeiGene, and China Biologic Products [3]

Core Viewpoint - The biopharmaceutical sector is currently underperforming due to multiple factors, including a lack of significant business development catalysts and external regulatory concerns, yet it remains crucial to maintain close attention to this sector as favorable macroeconomic conditions are emerging [1][2]. Group 1: Current Market Conditions - The biopharmaceutical sector is facing challenges such as the absence of major business development catalysts and the impact of potential regulatory measures from the Trump administration regarding Chinese innovative drugs [1]. - Recent volatility in stock prices, particularly in Hong Kong and A-shares, indicates a market correction that may lead to a focus on companies with genuine clinical value and performance [2]. Group 2: Investment Opportunities - The current environment presents a unique buying opportunity for high-quality innovative drug companies, as the market is expected to gradually shift towards those with proven clinical efficacy [2]. - The investment landscape for innovative drugs has entered an alpha phase, where stock selection factors are becoming more significant than market trends [2]. Group 3: Asset Rebalancing - The pharmaceutical sector may experience asset rebalancing across three dimensions: U.S.-China asset dynamics, a shift towards large-cap blue-chip companies, and internal balance within the sector, including medical devices and services [3].